Brief: Inhibikase Therapeutics Granted Pre-NDA Meeting With The FDA For IkT-001Pro
04/12/2023 13:44
Dec 4 (Reuters) - Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS GRANTED PRE-NDA MEETING WITH THE
FDA FOR
IKT-001PRO
* INHIBIKASE THERAPEUTICS INC - BIOEQUIVALENCE TO 400 MG AND
600
MG IMATINIB MESYLATE COMPLETED WITH MINIMAL ADVERSE EVENTS
* INHIBIKASE THERAPEUTICS-PRE NDA MEETING TO DISCUSS
REQUIREMENTS
FOR 505(B)(2) NDA SUBMISSION FOR IKT-001PRO IN UP TO 8
BLOOD,STOMACH CANCER INDICATIONS
Source text for Eikon: ID:nGNX4yXTgM
Further company coverage: IKT.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share
Brief: Inhibikase Therapeutics Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants
Brief: Inhibikase Therapeutics Advancing IKT-001 To Global Phase 3 Study In Pulmonary Arterial Hypertension
Cardiopulmonary drugmaker Inhibikase Therapeutics' Q3 net loss widens
Inhibikase Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary